NCT05277402View on ClinicalTrials.gov

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 9, 2022

Primary Completion Date

August 1, 2022

Study Completion Date

December 1, 2022

Conditions
Advanced/Metastatic Solid Tumors
Interventions
DRUG

ADG116

IV infusion

Trial Locations (2)

28078

Carolina BioOncology Institute, Huntersville

78229

Next Oncology, San Antonio

Sponsors

Lead Sponsor

Adagene Inc
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Adagene Inc

INDUSTRY

NCT05277402 - ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter